Liminatus Pharma (NASDAQ:LIMN) Releases Quarterly Earnings Results

Liminatus Pharma (NASDAQ:LIMN) released its earnings results on Tuesday. The company reported ($0.34) earnings per share (EPS) for the quarter, FiscalAI reports.

Liminatus Pharma Trading Up 3.5%

Shares of NASDAQ:LIMN traded up $0.01 on Wednesday, reaching $0.18. 160,209 shares of the company were exchanged, compared to its average volume of 8,751,722. The company has a 50-day moving average of $0.48 and a 200-day moving average of $0.88. The firm has a market cap of $5.53 million and a price-to-earnings ratio of -1.48. Liminatus Pharma has a 1-year low of $0.17 and a 1-year high of $33.66.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Friday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Liminatus Pharma currently has an average rating of “Sell”.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.